Table 3.

Treatment and electrocardiographic characteristics of the study population

Electrocardiographic Characteristics	Converted drugs
	total adenosine n (%)	total diltiazem n (%)	p
Visible P-wave	21 (46.7)	24 (53.3)	0.038
aVL notch	16 (41)	23 (59)	0.005
Pseudo-S-wave in leads II, III, and aVF	10 (71.4)	4 (28.6)	0.200
Pseudo-R’-wave in lead V1	12 (63.2)	7 (36.8)	0.475
AVNRT	13 (65)	7 (35)	0.168
Total	41 (56.2)	32 (43.8)
	6 mg adenosine n (%)	0.25 mg/kg diltiazem n (%)	P
Visible P-wave	14 (38.9)	22 (61.1)	0.006
aVL notch	15 (41.7)	21 (58.3)	0.024
Pseudo-S-wave in leads II, III, and aVF	9 (69.2)	4 (30.8)	0.215
Pseudo-R’-wave in lead V1	11 (61.1)	7 (38.9)	0.331
AVNRT	12 (63.2)	7 (36.8)	0.221
Total	34 (100)	29 (100)
	12 mg adenosine n (%)	0.35 mg/kg diltiazem n (%)	p
Visible P-wave	3 (60.0)	2 (40.0)	0.800
aVL notch	1 (33.3)	2 (66.7)	0.200
Pseudo-S-wave in leads II, III, and aVF	0 (0)	0 (0)
Pseudo-R’-wave in lead V1	0 (0)	0 (0)
AVNRT	0 (0)	0 (0)
Total	4 (100)	4 (100)